No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA
03-09-2019
UK faces medicine shortages after no deal: leaked govt report
21-08-2019
EMA settles Brexit dispute; issues drug shortages guidance
08-07-2019
andrewlinscott / iStockphoto.com
Several pharma bodies have signed non-disclosure agreements (NDAs) which prevent them from disclosing the UK government’s plans for a no-deal Brexit.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
non disclosure agreement, Pharmaceutical Services Negotiating Committee, British Generic Manufacturers Association, Brexit
